Imaging the effects of anti-angiogenic treatments

Quarterly Journal of Nuclear Medicine

Volumn 47, Issue 3, 2003, Pages 163-170

  Vavere A L ^a   Lewis, J S ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b USA   (United States)

Author keywords

Angiogenesis inhibitors; Neovascularization, pathologic, diagnosis; Neovascularization, pathologic, therapy

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 4 DEDIMETHYLAMINOSANCYCLINE; AE 941; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; ANTINEOPLASTIC AGENT; ATRASENTAN; CAPTOPRIL; CGS 27023A; CILENGITIDE; CM 101; COMBRETASTATIN; ENDOSTATIN; FUMAGILLOL CHLOROACETYLCARBAMATE; GADODIAMIDE; GADOLINIUM PENTETATE; IM 862; INTERLEUKIN 12; MARIMASTAT; MONOCLONAL ANTIBODY LM 609; N (4 BROMO 2 FLUOROPHENYL) 6 METHOXY 7 [2 (1H 1,2,3 TRIAZOL 1 YL)ETHOXY] 4 QUINAZOLINAMINE; PENICILLAMINE; PRINOMASTAT; PROTEIN FARNESYLTRANSFERASE INHIBITOR; REBIMASTAT; SEMAXANIB; SQUALAMINE; TANOMASTAT; TETRATHIOMOLYBDIC ACID; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN ANTIBODY; VATALANIB; ZDO 101; ZK 22584;

ANGIOGENESIS; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DOSE CALCULATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MONITORING; HUMAN; IMAGING; NON INVASIVE MEASUREMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHOTODYNAMIC THERAPY; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; REVIEW; TREATMENT PLANNING; TUMOR; TUMOR VASCULARIZATION; URINALYSIS;

ANGIOGENESIS INHIBITORS; DIAGNOSTIC IMAGING; HUMANS; MAGNETIC RESONANCE IMAGING; MICROSCOPY, CONFOCAL; MICROSCOPY, FLUORESCENCE; MICROSCOPY, FLUORESCENCE, MULTIPHOTON; MICROSCOPY, POLARIZATION; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED; ULTRASONOGRAPHY, DOPPLER;

EID: 0142011149     PISSN: 11243937     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Li WW. Tumor angiogenesis: Molecular pathology, therapeutic targeting, and imaging. Acad Radiol 2000;7:800-11.
2. Van De Wiele C, Oltenfreiter R, De Winter O, Signore A, Slegers G, Dierckx Rudi A. Tumour angiogenesis pathways: Related clinical issues and implications for nuclear medicine imaging. Eur J Nucl Med Mol Imaging 2002;29:699-709.
3. Costouros NG, Diehn FE, Libutti SK. Molecular imaging of tumor angiogenesis. J Cell Biochem 2002;39:72-8.
4. Blankenberg FG, Eckelman WC, Strauss HW, Welch MJ, Alavi A, Anderson C et al. Role of radionuclide imaging in trials of antiangiogenic therapy. Acad Radiol 2000;7:851-67.
5. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med 1995;1:27-31.
6. Angiogenesis Foundation website: http://www.angio.org.
7. Folkman J. The influence of angiogenesis research on management of patients with breast cancer. Breast Cancer Res Treat 1995;36:109-18.
8. Folkman J, Beckner K. Angiogenesis imaging. Acad Radiol 2000;7:783-5.
9. Cherrington JM, Strawn LM, Shawver LK. New paradigms for the treatment of cancer: The role of anti-angiogenesis agents. Adv Cancer Res 2000;79:1-38.
10. Sheehan JB, Bence AK, Adams VR. Antiangiogenesis agents as cancer therapy. J Am Pharm Assoc 2001;41:771-3.
11. Berlex Imaging website: http://www.berleximaging.com/product_magnevist.html
12. Brasch RC, Gossmann A, Helbich TH, Kuriyama N, Roberts TPL, Shames DM et al. Can a small-molecular gadolinium contrast agent be applied successfully with dynamic MRI to quantitatively define brain tumor microvascular responses to angiogenesis inhibition? Acad Radiol 2002;9 Suppl 2:S326-7.
13. Gossmann A, Helbich TH, Kuriyama N, Ostrowitzki S, Roberts TPL, Shames DM et al. Dynamic contrast-enhanced magnetic resonance imaging as a surrogate marker of tumor response to antiangiogenic therapy in a xenograft model of glioblastoma multiforme. J Magn Reson Imaging 2002;15:233-40.
14. Brasch R, Turetschek K. MRI characterization of tumors and grading angiogenesis using macromolecular contrast media: Status report. Eur J Radiol 2000;34:148-55.
15. Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Curwen JO, Hennequin LF et al. ZD4190: An orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy. Cancer Res 2000;60:970-5.
16. Clement O, Pradel C, Siauve N, Frouin F, Bruneteau G, Kahn E et al. Assessing perfusion and capillary permeability changes induced by a VEGF inhibitor in human tumor xenografts using macromolecular MR imaging contrast media. Acad Radiol 2002;9 Suppl 2:S328-9.
17. Su MY, Wang Z, Roth GM, Lao X, Samoszuk MK, Nalcioglu O. Pharmacokinetic changes induced by vasomodulators in kidneys, livers, muscles, and implanted tumors in rats as measured by dynamic Gd-DTPA-enhanced MRI. Magn Reson Med 1996;36:868-77.
18. Maxwell RJ, Wilson J, Prise VE, Vojnovic B, Rustin GJ, Lodge MA et al. Evaluation of the anti-vascular effects of combretastatin in rodent tumours by dynamic contrast enhanced MRI. NMR Biomed 2002;15:89-98.
19. Su M-Y, Samoszuk MK, Wang J, Nalcioglu O. Assessment of protamine-induced thrombosis of tumor vessels for cancer therapy using dynamic contrast-enhanced MRI. NMR Biomed 2002;15:106-13.
20. 150-water for monitoring prostate cancer during a phase II anti-angiogenic drug trial with thalidomide. Clin Positron Imaging 2000;3:144.
21. Mullani NA, Herbst RS, Abbruzzese JL, Charnsangavej C, Kim E, Tran H et al. Non-linear response of blood flow and glucose metabolism in human tumors treated with antiangiogenic agent endostatin. J Nucl Med 2001 42:298P.
22. 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res 2001;61:1781-5.
23. Ogawa M, Hatano K, Oishi S, Kawasumi Y, Fujii N, Kawaguchi M et al. Direct electrophilic radiofluorination of a cyclic RGD peptide for in vivo avb3 integrin related tumor imaging. Nucl Med Biol 2003;30:1-9.
24. Vavere AL, Jones LR, McCarthy TJ, Rowland DJ, Welch MJ. Preparation, biodistribution, and microPET imaging of yitanium-45-transferrin. J Label Comp Radiopharm 2001;44:793-5.
25. Vavere AL, Lewis JS, Welch MJ. Imaging of anti-angiogenic treatments: Ti-45-transferrin microPET as a surrogate marker for tumor response. Technetium, Rhenium and Other Metals in Chemistry and Nuclear Medicine 2002;6:101-5.
26. Jayson GC, Zweit J, Jackson A, Mulatero C, Julyan P, Ranson M et al. Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: Implications for trial design of antiangiogenic antibodies. J Natl Cancer Inst 2002;94:1484-93.
27. Valesky M, Spang AJ, Fisher GW, Farkas DL, Becker D. Noninvasive dynamic fluorescence imaging of human melanomas reveals that targeted inhibition of bFGF or FGFR-1 in melanoma cells blocks tumor growth by apoptosis. Mol Med 2002;8:103-12.
28. Bremer C, Tung C-H, Weissleder R. Molecular imaging of MMP expression and therapeutic MMP inhibition. Acad Radiol 2002;9:Suppl 2:S314-5.
29. Brown EB, Campbell RB, Tsuzuki Y, Xu L, Carmeliet P, Fukiumura D et al. In vivo measurement of gene expression, angiogenesis and physiological function in tumors using multiphoton laser scanning microscopy. Nat Med 2001;7:864-8.
30. Jain RK, Munn LL, Fukumura D. Dissecting tumour pathophysiology using intravital microscopy. Nat Rev Cancer 2002;2:266-76.
31. Read TA, Farhadi M, Bjerkvig R, Olsen BR, Rokstad AM, Huszthy PC et al. Intravital microscopy reveals novel antivascular and antitumor effects of endostatin delivered locally by alginate-encapsulated cells. Cancer Res 2001;61:6830-7.
32. Dolmans DEJGJ, Kadambi A, Hill JS, Waters CA, Robinson BC, Walker JP et al. Vascular accumulation of a novel photosensitizer, MV6401, causes selective thrombosis in tumor vessels after photodynamic therapy. Cancer Res 2002;62:2151-6.
33. Dolmans DEJGJ, Kadambi A, Hill JS, Flores KR, Gerber JN, Walker JP et al. Targeting tumor vasculature and cancer cells in orthotopic breast tumor by fractionated photosensitizer dosing photodynamic therapy. Cancer Res 2002;62:4289-94.
34. Groner W, Winkelman JW, Harris AG, Ince C, Bouma GJ, Messmer K et al. Orthogonal polarization spectral imaging: A new method for study of the microcirculation. Nat Med 1999;5:1209-13.
35. Pahernik S, Harris AG, Schmitt-Sody M, Krasnici S, Goetz AE, Dellian M et al. Orthogonal polarisation spectral imaging as a new tool for the assessment of antivascular tumour treatment in vivo: A validation study. Br J Cancer 2002;86:1622-7.
36. Gee MS, Saunders HM, Lee JC, Sanzo JF, Jenkins WT, Evans SM et al. Doppler ultrasound imaging detects changes in tumor perfusion during antivascular therapy associated with vascular anatomic alterations. Cancer Res 2001 61:2974-82.
37. Miles KA. Functional computed tomography in oncology. Eur J Cancer 2002;38:2079-84.
38. Tateishi U, Kusumoto M, Nishihara H, Nagashima K, Morikawa T, Moriyama N. Contrast-enhanced dynamic computed tomography for the evaluation of tumor angiogenesis in patients with lung carcinoma. Cancer 2002;95:835-42.